Overcoming The Bias Against Medtech Entrepreneurship In Europe: An Interview With Martin Rothman

Why are European physicians so far ahead of the curve when it comes to innovative clinical practice and so far behind when it comes to creating companies? Interventional cardiologist and serial entrepreneur Martin Rothman offers some answers.

Nearly everyone in the medical device industry acknowledges the role physicians play in medtech innovation. In the US, the connection has led to the breeding of a special kind of executive: the physician-entrepreneur, a person trained in medicine who moves successfully into the world of industry and company creation. But historically in Europe, the connection has more often led in the opposite direction. More than just uncomfortable with the idea of mixing clinical practice and entrepreneurship, European physicians for many years actively discouraged and stigmatized colleagues who ventured into company creation. Interventional cardiologist, entrepreneur, and now big-company executive Martin Rothman, MD, has a long history nurturing not just new ideas for medical devices but also the companies that launch them, and he himself experienced the unforgiving looks and, early on, rarely shared with colleagues what he was doing in what might be called the more entrepreneurial side of device innovation.

In more recent years, Rothman has turned 180 degrees and now spends part of his time advising young would-be physician-entrepreneurs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

More from In Vivo

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.